Kenvue profitability rallies in Q1 as margins expand ahead of strategic deal

Kenvue (NYSE:KVUE) reported a strong start to the 2026 fiscal year, characterized by significant bottom-line growth and a marked improvement in operational efficiency.

For the fiscal first quarter ended March 29, 2026, the world’s largest pure-play consumer health company by revenue posted net sales of $3.89 billion, a 4.5% increase compared to the prior-year period.

The sales growth was primarily driven by a 3.8% benefit from foreign currency fluctuations, while organic sales grew by a modest 0.7%.

Despite the lean organic growth, Kenvue demonstrated high levels of internal efficiency, with adjusted gross profit margin expanding to 60.8%, up from 60% a year ago.

This margin improvement was fueled by favorable value realization and supply chain optimizations.

Kenvue’s profitability metrics saw a sharp upward trajectory during the quarter.

Operating income margin rose to 19.6% from 14.9%, while adjusted operating income margin expanded significantly to 24.0% from 19.8%.

This 420-basis-point expansion reflects the company's successful efforts to streamline its cost structure following its separation from Johnson & Johnson.

The margin strength translated into robust earnings growth.

While diluted EPS increased to $0.25 compared to $0.17 in the prior-year period, adjusted diluted EPS rose 33% to $0.32, surpassing the $0.24 reported in the first quarter of 2025.

A major focal point for the quarter remains the company's strategic evolution.

Kenvue is currently in the midst of a significant transaction involving Kimberly-Clark, a move expected to further refine its brand portfolio and geographic footprint.

Citing the pending nature of this transaction, Kenvue management took the atypical step of withholding forward-looking guidance for the remainder of the 2026 fiscal year.